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Abstract Prostaglandin E2 receptors (EPR), which belong to 
the family of heterotrimeric G protein-coupled ectoreceptors with 
seven transmembrane domains, can be classified into four 
subtypes according to their ligand binding and G protein 
coupling specificity. Of these, EP3ßR is coupled to G¡, whereas 
EP4R is coupled to Gs. EP4R, in contrast to EP3ßR, shows 
agonist-induced desensitization. The C-terminal domain and the 
third intracellular loop of these receptors have been implicated in 
G protein coupling specificity and desensitization. Here, receptor 
hybrids consisting of the main portion of rat EP3ßR and either 
the C-terminal domain or the third intracellular loop of human 
EP4R were used to study the contribution of the respective 
receptor domains to G protein coupling and desensitization. 
Neither the EP4R C-terminal domain nor the EP4R third 
intracellular loop alone was sufficient to change the coupling 
specificity of the rEP3hEP4 receptor hybrids from G¡ to Gs or to 
confer additional Gs coupling. However, the EP4R C-terminal 
domain but not the third intracellular loop was necessary and 
sufficient to mediate rapid agonist-induced, second messenger-
independent desensitization in the G¡-coupled hybrid receptors. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Prostaglandin E2 receptors (EPR), like most prostanoid re-
ceptors, belong to the class of G protein-coupled ectorecep-
tors with seven transmembrane domains [1]. There are four 
subtypes of EPR that differ in their affinity to synthetic li-
gands and their G protein coupling specificity: EPiR are 
linked to Gq and increase InsP3 and hence the cytosolic 
Ca2+ concentration, EP2R and EP4R are coupled to Gs and 
increase intracellular cAMP, while EP3R are coupled to G¡ 
and decrease hormone-stimulated cAMP formation [2]. These 
receptors display an overall sequence homology of about 50%, 
with the putative transmembrane domains being most con-
served [3]. So far, little is known about the structure-function 
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relationship of these receptors. A couple of highly conserved 
amino acids have been shown to be necessary for ligand bind-
ing, i.e. the Arg corresponding to Arg310 in the seventh trans-
membrane domain of the rat EP3ßR [4], or signal transduction 
to the G protein, i.e. the amino acid corresponding to Asp319 
in the seventh transmembrane domain of rat EP3R [5]. The C-
terminal domain has been implicated in control of agonist-
dependent coupling to G proteins. A mutant receptor, which 
was truncated beginning 10 amino acids after the end of the 
seventh transmembrane domain, was constitutively active but 
showed no ligand-dependent coupling control [6,7]. In order 
to further elucidate the role of the C-terminal domain in G 
protein coupling, in a previous study a receptor hybrid was 
generated consisting of the N-terminal main portion of the 
Gi-coupled EP3pR up to the end of the seventh transmem-
brane domain and the C-terminal portion of the Gs-coupled 
EP4R [8]. In this receptor hybrid which was coupled to G¡ 
exclusively the C-terminal domain of the EP4R restored the 
agonist-dependent coupling control that was lost in the trun-
cated EP3R. A second function that has been attributed to the 
C-terminal domain in EPRs is the agonist-induced receptor 
desensitization. EP3oLR and EP3ßR are splice variants that 
differ in their C-terminal domain. Of these, only EP3oLR 
showed agonist-dependent desensitization [9]. Furthermore, 
of the two Gs-linked EPRs, EP2R and EP4R, only EP4R 
has a long serine- and threonine-rich C-terminal domain 
and shows rapid agonist-induced desensitization [10]. While 
the current study was under way, it was shown by C-terminal 
truncation of the EP4R that the C-terminal domain is neces-
sary for agonist-induced desensitization but not for G protein 
coupling [11]. Here, the role of the C-terminal domain in 
receptor desensitization of EPRs was studied in receptor hy-
brids. It was found that the C-terminal domain (Ct) of EP4R 
in a rEP3hEP4-Ct receptor hybrid is not only necessary but 
sufficient to confer ligand-induced receptor desensitization 
while the third intracellular domain (Uli) of the EP4R did 
not confer desensitizability in a rEP3hEP4-IIIi receptor hy-
brid. 
2. Materials and methods 
2.1. Materials 
All materials were of analytical grade and from commercial sources. 
M&B 28767 was a generous gift from Rhone-Poulenc Rorer (Dagen-
ham, UK). [3H]PGE2 was obtained from Amersham (Braunschweig, 
Germany), unlabeled prostaglandins were purchased from Serva (Hei-
delberg, Germany) or Calbiochem-Novabiochem (Bad Soden, Ger-
many) who also provided pertussis toxin (PTX). Geneticin (G418 
sulfate) and cell culture media were obtained from Gibco-BRL (Eg-
genstein, Germany), forskolin was from ICN (Meckenheim, Ger-
many). Primers (Table 1) were synthesized by Pharmacia (Freiburg, 
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Germany) or NAPS (Göttingen, Germany). The sources of other ma-
terials are given in the text. 
2.2. Construction of the chimeric rEP<¡hEPjl receptor cDNAs 
Cloning of the rEP3ßR [12] and hEP4R [8] cDNAs was carried out 
as described previously. The cDNA for the chimeric rEP3hEP4-CtR 
and rEP3hEP4-IIIiR were constructed by recombinant PCR technol-
ogy [13]. The protocol for the construction of rEP3hEP4-CtR cDNA 
has been described in detail elsewhere [8]. The rEP3hEP4-IIIiR cDNA 
was generated using the cDNAs of rEP3pR and hEP4R cloned into 
PUC 18 as templates. The N-terminal portion of rEP3pR up to the 
end of the 5th transmembrane domain, the third intracellular loop of 
hEP4R and the C-terminal portion of rEP3pR starting at the 6th 
transmembrane domain were amplified by PCR in separate reactions 
using primer pairs P1/P2 and P5/P6 for the N-terminal and C-terminal 
portions of rEP3pR and P3/P4 for the hEP4R third intracellular loop 
(Table 1). Primers P2 and P5 hybridized with their 3'-part to the 
rEP3R template and were complementary to the hEP4R cDNA with 
their overhanging 5'-part. Similarly, primers P3 and P4 hybridized 
with hEP4R with their 3'-part and were complementary to sequences 
of rEP3pR with their 5'-overhanging ends. The 873 bp (N-terminal 
rEP3pR fragment), 231 bp (hEP4R third intracellular loop) and 536 bp 
(C-terminal hEP4R fragment) PCR products were isolated, mixed and 
fused in a third PCR using the primer pair P1/P6. All PCRs were 
performed with the proofreading PWO polymerase (Boehringer, 
Mannheim, Germany) with 10 ng template and 35 cycles of the fol-
lowing temperature profile: 1 min 95°C, 1 min 55°C and 2 min 72°C. 
The resultant 1592 bp cDNA fragment was cloned into PUC 18 and 
verified by DNA sequencing. 
2.3. Stable expression of rat EP3p receptor in CHO and rEP shEP¡^-Ct 
receptor and rEPghEP/t-IIH receptor in HepGg cells 
Stable expression of rEP3pR in CHO cells was carried out as de-
scribed previously [7]. The 1.66 kbp Not\ cDNA fragment for 
rEP3hEP4-CtR and the 1.6 kbp Hindlll cDNA fragment of 
rEP3hEP4-IIIiR were subcloned into the eukaryotic expression vector 
pRc/CMV (Invitrogen). 20 μg of the resultant plasmid was linearized 
and transfected into 107 cells by electroporation (CHO cells) or a 
calcium phosphate method using 5% (v/v) MBS (HepG2 cells). Trans-
fectants were isolated in HAM-F12 containing 10% FCS and 1.2 mg/ 
ml G418 (CHO cells) or MEM containing 10% (v/v) FCS and 0.5 mg/ 
ml G418 (HepG2 cells) as substrate of the selection marker amino-
glycoside phosphotransferase (NEO). Clonal cell lines were isolated 
by single cell cloning and tested for expression by PGE2 binding. 
hEP4R was transfected transiently into HepG2 cells by the DEAE-
dextran method as described previously [8]. 
2.4. PGEg binding assays with transfected HepGg or CHO cells 
CHO cells stably expressing rEP3pR and HepG2 cells stably ex-
pressing the chimeric receptors were cultured in 6 cm diameter plates 
to a density of 1.5 XlO6 in HAM-F12 medium containing 10% (v/v) 
FCS for CHO cells and 0.5 mg/ml G418 or MEM containing 10% 
FCS and 0.5 mg/ml G418 for HepG2 cells. For ligand binding studies 
cells were washed three times with 5 ml HEPES buffer pH 7.4 con-
taining 140 mM NaCl, 4.7 mM KC1, 2.2 mM CaCl2, 1.2 mM 
KH 2 P0 4 , 11 mM glucose and 15 mM HEPES (incubation buffer) 
and then preincubated for 5 min in the same buffer with or without 
100 nM M&B 28767. The agonist was removed by two washes with 
incubation buffer, an acid wash with 5 ml of 50 mM glycine, 150 mM 
NaCl pH 3 for 1 min and two additional washes with incubation 
buffer. Cells were then detached from the tissue culture plates with 
250 μΐ Ca2+-free incubation buffer containing 1 mM EDTA. Of this 
cell suspension 50 μΐ was incubated in a total volume of 100 μΐ with 10 
nM [3H]PGE2 for 30 min at 37°C. Non-specific binding was deter-
mined in the presence of 10 μΜ PGE2. Bound and unbound ligand 
were separated by rapid vacuum filtration through GF 52 filters 
(Schleicher&Schüll, Dassel, Germany). Filters were washed four times 
with 4 ml ice-cold binding buffer. Radioactivity retained on the filter 
was counted in 5 ml Hydroluma (Baker, Deventer, Netherlands). 
2.5. cAMP formation in transfected CHO or HepGg cells 
CHO cells stably expressing rEP3pR and HepG2 cells stably ex-
pressing the chimeric receptors were cultured in 3.5 cm diameter plates 
to a density of 5XlO5 in HAM-F12 medium containing 10% (v/v) 
FCS for CHO cells and 1.2 mg/ml G418 or MEM containing 10% 
FCS and 0.5 mg/ml G418 for HepG2 cells. cAMP assays with HepG2 
cells transiently transfected with hEP4R were performed 72 h after 
transfection. Where indicated, cells were pretreated with PTX (100 ng/ 
ml) for 16 h. Cells were washed three times with 1 ml incubation 
buffer and then preincubated in 1 ml of the same buffer with or 
without 100 nM M&B 28767 for 5 min. The agonist was removed 
as described for the binding studies. Cells were preincubated with 1 ml 
incubation buffer containing 1 mM IBMX at 37°C for 10 min. Then 
PGE2, M&B 28767 and forskolin (100 μΜ) were added in a volume of 
10 μΐ buffer to the final concentration indicated. After incubation for 
10 min the reaction was stopped by removing the buffer and freezing 
the cells in liquid nitrogen. Cells were lysed in 500 μΐ 10 mM HC1 
containing 1 mM IBMX for 1 h at 4°C. The lysate was centrifuged 
and cAMP was quantified in the supernatant with a 125I-cAMP assay 
kit of Amersham (Braunschweig, Germany). 
3. Results 
3.1. G protein coupling specificity 
Exchange of the C-terminal domain of the G¡-coupled ΕΡ3β 
receptor starting directly after the putative seventh transmem-
brane domain with the C-terminal domain of the Gs-coupled 
EP4 receptor yielded a receptor hybrid (rEP3hEP4-Ct recep-
tor) that had similar binding characteristics as the wild type 
receptor (not shown) and was coupled exclusively to G¡ (Fig. 
lc). As with the wild type receptor (Fig. la), PGE2 reduced 
the forskolin-stimulated cAMP formation to about 20% of the 
maximum. This inhibition was attenuated by pretreatment of 
the cells with PTX (not shown). No Gs-mediated PGE2-de-
pendent increase in cAMP formation, which is typical for wild 
type EP4R (Fig. lb), was observed in cells expressing the 
Table 1 
Sequence and location of the PCR primers used to generate the hybrid receptors 
Sequence (5'-3') Receptor and position 
PI AGCGACCGGCGCTCAGCTGG 
P2 GGCGGTGCATGCGGAGCAGCGCGCC/ 
GATGGTCGCCAGGTTGCAGGCAAA 
P3 TTTGCCTGCAACCTGGCGACCATC/ 
GGCGCGCTGCTGCGCATGCACCGC-3' 
P4 ACACACATGATCCCCATAAG/ 
GATCTCGGCGCCCGCGATGCGGCG 
P5 inverted complementary sequence of P4 (forward) 
P6 CTGAGGCTGGAGATATTTCTGCACTGAGTC 
sequence flanking the EcoRl site of the vector Xgtl 1 (short arm), 
originally used to amplify the rEP3pR cDNA cloned in Xgtll [7] 
(forward) 
hEP4R pos. 1034-1110, Ace. No. L28175/ 
rEP3pR pos. 792-769, Ace. No. X80133 (reverse) 
rEP3p pos. 769-792/ 
hEP4 pos. 1010-1033 (forward) 
rEP3pR pos. 902-883/ 
hEP4R pos. 1192-1169 (reverse) 
located in the 3'-UTR of the rEP3pR cDNA 121 bp after the stop 
codon (reverse) 
The locations given are the sequence positions in the data files retrieved from GenBank under the accession numbers indicated. The reverse primers 
are the complementary sequences to the indicated positions. Primers are shown in the 5' to 3' direction. The EP3pR sequences are shown in italics. 
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rEP3hEP4-Ct receptor hybrid. Similarly, the rEP3hEP4-IIIi 
receptor hybrid, containing the third intracellular loop of hu-
man EP4R from the end of the fifth to the beginning of the 
sixth putative transmembrane domain, showed identical bind-
ing characteristics to wild type EP3ßR (not shown) and was 
coupled exclusively to a PTX-sensitive (not shown) G¡ pro-
tein. In cells expressing the rEP3hEP4-IIIi receptor hybrid 
(Fig. Id) PGE2 reduced forskolin-stimulated cAMP formation 
to a similar extent as in cells expressing wild type EP3ßR (Fig. 
la). The ΓΕΡ31ιΕΡ4-ΠΙί receptor hybrid did not couple to Gs. 
Thus, neither the C-terminal domain nor the third intracellu-
lar loop alone contained sufficient information to shift the 
coupling specificity of the hybrid receptors from G¡ to Gs. 
3.2. Induction of desensitizability by the EP^R C-terminal 
domain but not the EP¿R third intracellular loop 
Cells stably expressing either wild type EP3ßR, rEP3hEP4-
Ct or the rEP3hEP4-IIIi receptor hybrids were preincubated 
with a saturating concentration of the EP3R agonist M&B 
28767 (100 nM) for 5 min. The agonist was then completely 
removed (see Section 2). In cells expressing the wild type 
receptor or the rEP3hEP4-IIIi receptor hybrid, containing 
the third intracellular loop of the hEP4R, preincubation did 
not reduce specific PGE2 binding of 10 nM [3H]PGE2. By 
contrast, preincubation with the EP3 agonist of cells express-
ing the rEP3hEP4-Ct receptor hybrid, containing the hEP4R 
C-terminal domain, reduced specific [3H]PGE2 binding to 60% 
Fig. 2. Induction by the hEP4R C-terminal domain of desensitizabil-
ity in the rEP3hEP4-Ct receptor hybrid. Cells were transfected stably 
as described in the legend to Fig. 1 either with the wild type pRc/ 
CMV/rEP3pR or with one of the hybrid receptor pRc/CMV/ 
rEP3hEP4-Ct or pRc/CMV/rEP3hEP4-IIIi constructs. In a preincu-
bation period cells were exposed to a saturating concentration (100 
nM) of the EP3R agonist M&B 28767 for 5 min. The agonist was 
then removed by an acid wash followed by extensive washing with 
incubation medium (see Section 2). For binding assays cells were de-
tached from the tissue culture plates with EDTA buffer. Binding 
was measured in the cell suspension in presence of 10 nM [3H]PGE2 
with 10 μΜ unlabelled PGE2 to determine unspecific binding after 
30 min at 37°C. cAMP formation was determined by radioimmuno-
assay in cell cultures after stimulation for 10 min with 1 μΜ forsko-
lin and 5 nM M&B 28767. Values are means ± S.E.M. percent of 
control cells tested in parallel that were not exposed to the agonist 
in the preincubation period. Student's i-test for paired samples: 
*P<0.05. 
of the untreated control (Fig. 2). Likewise, the M&B 28767-
dependent inhibition of forskolin-induced cAMP formation 
was not attenuated by agonist pretreatment in cells expressing 
either wild type EP3ßR or the rEP3hEP4-IIIi receptor hybrid, 
yet was reduced to about 50% in cells expressing the 
rEP3hEP4-Ct receptor hybrid (Fig. 2). Thus, the EP4R C-ter-
minal domain but not the third intracellular loop of the EP4R 
conferred agonist-induced desensitization to the hybrid recep-
tors. 
Fig. 1. G protein coupling specificity of wild type and hybrid recep-
tors. CHO cells were stably transfected with the pRc/CMV/rEP3ßR 
construct (a). HepG2 cells were stably transfected with the pRc/ 
CMV/rEP3hEP4-Ct construct (c) or the pRc/CMV/rEP3hEP4-IIIi 
construct (d) or they were transfected transiently with the pcDNA 
I/AMP/hEP4R construct (b). cAMP formation induced by 1 μΜ 
forskolin, 1 μΜ PGE2 or 1 μΜ forskolin+1 μΜ PGE2 after 10 min 
at 37°C was determined by radioimmunoassay. cAMP formation in 
forskolin-stimulated (a,c,d) or unstimulated cells (b), respectively, 
was set at 100%. Values are means ± S.E.M. of three different ex-
periments performed in duplicate, n.d., not determined. Statistics: 
Student's i-test for unpaired samples: a, P<0.05. 
3.3. Time course of desensitization 
Cells expressing wild type EP3ßR, the rEP3hEP4-Ct receptor 
hybrid or the rEP3hEP4-IIIi receptor hybrid were preincu-
bated for 1 h in incubation buffer. At different times prior 
to the end of the preincubation period a saturating concen-
tration of the EP3R agonist M&B 28767 (100 nM) was added. 
At the end of the preincubation period the agonist was re-
moved by an acid wash and the inhibition of forskolin-in-
duced cAMP formation by 5 nM M&B 28767 was determined 
as detailed above. In cells expressing either wild type EP3ßR 
or the rEP3hEP4-IIIi receptor hybrid pretreatment with 
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M&B28767 for different times did not affect the later M&B 
28767-dependent inhibition of forskolin-induced cAMP for-
mation (Fig. 3). Throughout the time course 5 nM M&B 
28767 reduced forskolin-induced cAMP formation in control 
cells by between 4/5th and 9/10th (not shown). This was set at 
100% inhibition. In cells expressing the rEP3hEP4-Ct receptor 
hybrid (Fig. 3) the inhibition of forskolin-stimulated cAMP 
formation was reduced almost to the minimum of 60% al-
ready after 2 min. The minimum was reached after 10 min 
of preincubation. With 1 h of preincubation desensitization 
was no longer observed (Fig. 3). Thus, the agonist-induced 
desensitization of the rEP3hEP4-Ct receptor hybrid was rapid 
and transient. 
3.4. Modulation of the dose response curve by desensitization 
In untreated cells expressing either wild type EP3ßR, the 
rEP3hEP4-Ct receptor hybrid or the rEP3hEP4-IIIi receptor 
hybrid M&B 28767 inhibited the forskolin-induced cAMP 
formation with an ED50 of 7X10"9 M, 10"9 M and 
2X 10~9 M, respectively. At saturating concentrations the for-
skolin-induced cAMP formation was reduced by 9/10th with 
all three receptors (Fig. 4). In cells expressing wild type EP3ßR 
or the rEP3hEP4-IIIi receptor hybrid preincubation for 5 min 
with 100 nM M&B 28767 did not affect the ED50 or the 
maximal inhibition. By contrast, in cells expressing the 
rEP3hEP4-Ct receptor hybrid preincubation with M&B 
28767 increased the ED50 by about half an order of magni-
tude. In addition, the maximal inhibition was attenuated: at 
saturating agonist concentrations forskolin-stimulated cAMP 
formation was reduced by only about 60%. Thus, the agonist-
induced desensitization of the rEP3hEP4-Ct receptor hybrid 
appeared to reduce both receptor affinity and number of func-
tionally coupled receptors. 
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Fig. 3. Time dependence of desensitization of the EP3hEP4-Ct re-
ceptor hybrid. Cells were transfected stably as described in the 
legend to Fig. 1 either with the wild type pRc/CMV/rEP3ßR or with 
one of the hybrid receptor pRc/CMV/rEP3hEP4-Ct or pRc/CMV/ 
rEP3hEP4-IIIi constructs. In a preincubation period cells were ex-
posed to a saturating concentration (100 nM) of the EP3R agonist 
M&B 28767 for the time indicated. The agonist was then removed 
by an acid wash followed by extensive washing with incubation me-
dium (see Section 2). cAMP formation was determined by radioim-
munoassay in these cell cultures after stimulation for 10 min with 
1 μΜ forskolin and 5 nM M&B 28767. Values are means ±S.E.M. 
percent of control cells tested in parallel that were not exposed to 
the agonist in the preincubation period (n = 4). 
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Fig. 4. Modulation by desensitization of the dose dependence of the 
M&B 28767-mediated inhibition of forskolin-induced cAMP forma-
tion by the EP3hEP4-Ct receptor hybrid. Cells were transfected sta-
bly as described in the legend to Fig. 1 either with the wild type 
pRc/CMV/rEP3ßR or with one of the hybrid receptor pRc/CMV/ 
rEP3hEP4-Ct or pRc/CMV/rEP3hEP4-IIIi constructs. Where indi-
cated, cells were exposed to a saturating concentration (100 nM) of 
the EP3R agonist M&B 28767 in a preincubation period of 5 min. 
The agonist was then removed by an acid wash followed by exten-
sive washing with incubation medium (see Section 2). cAMP forma-
tion was determined by radioimmunoassay in cell cultures after 
stimulation for 10 min with 1 μΜ forskolin and the indicated con-
centration of M&B 28767. cAMP formation after forskolin stimula-
tion was set at 100%. Values are means ± S.E.M. (n = 4). 
4. Discussion 
4.1. G protein coupling specificity 
Receptor domains involved in G protein coupling have 
been analyzed in several G protein-coupled receptors 
(GPCR). A unifying principle has not emerged. In different 
systems the second and third intracellular loops as well as the 
C-terminal domain have been shown to contribute to G pro-
tein coupling specificity. Thus, substitution of the third intra-
cellular domain of the Gq-coupled muscarinic Ml receptor 
with the loop of the Gs-coupled ß-adrenergic receptor led to 
an additional Gs coupling [14,15]. However, in the Gs-coupled 
ß-adrenergic receptor substitutions in the second and third 
loops with sequences of the G¡-coupled 0C2-adrenergic receptor 
caused only decreased Gs coupling but conferred no G¡ cou-
pling [16]. Four splice variants of bovine EP3R, which differed 
only in their C-terminal sequence, coupled to different G pro-
teins [17], implying that the C-terminal domain might contain 
sufficient information to determine G protein coupling specif-
icity. However, seven C-terminal splice variants of human 
EP3R [18], which are in part highly homologous to the se-
quence of the bovine EP3R C-terminal domains, were all ex-
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clusively coupled to G¡ protein. In line with these latter re-
sults, the current study showed (Fig. 1) that neither the third 
intracellular loop nor the C-terminal domain of the Gs-
coupled human EP4R alone contained sufficient information 
to switch coupling specificity from G¡ to Gs or to confer addi-
tional Gs coupling in the rEP3hEP4-IIIi and rEP3hEP4-Ct 
receptor hybrids containing main portions of the G¡-coupled 
rat EP3pR. 
4.2. Site conferring agonist-induced desensitization of the 
rEPghEPj-Ct receptor hybrid 
Rapid agonist-induced desensitization is a common mecha-
nism to interrupt the intracellular signal propagation of many 
GPCR, primarily those coupled to Gs but also those coupled 
to Gj and Gq [19]. It had previously been shown that of the 
two Gs-linked PGE2RS only EP4R but not EP2R underwent 
rapid agonist-induced desensitization [10]. The presence of 
potential phosphorylation sites in the large C-terminal domain 
and/or the third intracellular loop of EP4R that are missing in 
EP2R have been implicated in this process. The role of the C-
terminal domain is underscored by the recent finding of a loss 
of desensitization in a C-terminally truncated EP4R [11]. The 
current study showed that the C-terminal domain of the EP4R 
is necessary and also sufficient to confer rapid agonist-induced 
desensitization in a hybrid receptor, while the third intracel-
lular loop of the EP4R was neither necessary nor sufficient to 
mediate agonist-induced desensitization (Fig. 2). This is in line 
with the results obtained with a chimeric ß3/ß2-adrenergic re-
ceptor, in which the C-terminal domain of the desensitizable 
ß2-adrenergic receptor conferred agonist-induced desensitiza-
tion to the non-desensitizable ß3-adrenergic receptor [20]. 
4.3. Possible mechanism of agonist-induced desensitization of 
the rEP3hEP4-CtR 
Agonist-induced receptor desensitization of GPCR has been 
shown to be mediated by receptor phosphorylation through 
either second messenger-dependent kinases or G protein-
coupled receptor kinases (GRK). 
4.3.1. PKA-mediated desensitization. Phosphorylation of 
PKA sites (RRXS) in the third intracellular loop and the C-
terminal domain has been discussed as a possible mechanism 
of EP4R desensitization [10]. From the current study a PKA-
dependent phosphorylation as the only mechanism of receptor 
desensitization can be excluded, since the rEP3hEP4-Ct recep-
tor hybrid did not mediate an agonist-dependent increase in 
cAMP formation (Fig. 1) and hence activation of protein 
kinase A. 
4.3.2. PKC-mediated desensitization. In cells transfected 
with an epitope-tagged human IP receptor [21], iloprost in-
creased cAMP and, at higher concentrations, InsP3 formation. 
Receptor phosphorylation occurred only at iloprost concen-
trations that stimulated InsP3 formation and was inhibited by 
PKC inhibitors but not by PKA inhibitors. Therefore, a PKC-
dependent phosphorylation has been implicated in the desen-
sitization and sequestration of the human prostacyclin recep-
tor. The C-terminal domain of the EP4R contains five poten-
tial phosphorylation sites for PKC (SXK/R). However, a 
PKC-dependent phosphorylation of rEP3EP4-CtR as the 
sole mechanism of desensitization seems to be unlikely since 
in transfected cells agonist exposure did not lead to an in-
crease in InsP3 formation (not shown) and thus, by inference, 
also not to DAG-dependent PKC activation. 
4.3.3. GRK-mediated desensitization. The C-terminal do-
main of the EP4R contains, in addition to potential PKA and 
PKC phosphorylation sites, a large number of potential phos-
phorylation sites for GRKs, which have no strict recognition 
sequence but seem to prefer Ser or Thr residues that are 
preceded by an Asp or Glu at a distance of 2-3 amino acids 
[21]. GRK-dependent phosphorylation of Ser and Thr resi-
dues in the C-terminal domain has been shown to mediate 
receptor desensitization of the ß-adrenergic [22] receptor and 
of rhodopsin [23] and thus is a likely mechanism also for the 
agonist-induced desensitization of the rEP3hEP4-Ct receptor 
hybrid. While in most receptors phosphorylation of the C-
terminal domain seems to mediate the agonist-induced desen-
sitization that is independent of second messenger-activated 
kinases, a GRK-dependent phosphorylation of the third intra-
cellular loop has been shown to mediate the agonist-induced 
desensitization of the 012-adrenergic receptor [24]. Yet, the 
third intracellular loop of EP4R can be excluded as the sole 
site mediating EP4R desensitization since the third intracellu-
lar loop of EP4R did not confer agonist-induced desensitiza-
tion to the rEP3hEP4-IIIi receptor hybrid (Fig. 2). 
4.4. Mode of desensitization 
4.4.1. Modulation of affinity and maximal response. Rapid 
agonist-induced desensitization of the rEP3hEP4-Ct receptor 
hybrid reduced both its affinity towards the ligand and the 
maximal biological response (Fig. 4). This is similar to the 
desensitization of the Gs-coupled ß2-adrenergic receptor 
which was accompanied by both reduction of affinity and 
maximal response already after 2 min of agonist exposure 
[25] and the desensitization pattern of the parent EP4R [10] 
whose C-terminus was incorporated into the receptor hybrid. 
However, rapid GRK-mediated desensitization of the G¡-
coupled 0C2-adrenergic receptor only decreased its affinity for 
the ligand and not the maximal response [24]. Similarly, brief 
exposure to PGE2 reduced the ED50 but not the maximal 
response of the G¡-coupled EP3aR [9]. Only after long-term 
exposure to their respective agonist (24 h) both receptors 
showed reduced maximal biological responsiveness [24,9]. 
Thus, rapid reduction of the maximal biological response 
may by typical of Gs-coupled receptors. This hypothesis is 
at variance with the mode of desensitization of a ß3/ß2-adren-
ergic receptor hybrid which showed only a reduced affinity but 
a normal maximal response in a cAMP assay after 30 min of 
agonist exposure [20]. However, the same paper reports a 20% 
reduction of maximal ligand binding after 15 min of agonist 
exposure. The discrepancy of full biological effect despite re-
duced maximal binding might be due to a large number of 
spare receptors in the receptor-overexpressing cells. 
4.4.2. Resensitization. Surprisingly, the agonist-induced 
desensitization of the rEP3hEP4-Ct receptor hybrid was tran-
sient. This contrasts with the ß2-adrenergic receptor whose 
affinity and maximal response continued to decline over a 
period of 180 min of agonist exposure. This might reflect 
the fact that in the ß-adrenergic receptor system GRKs and 
PKA can act in tandem [26]. The very early GRK-mediated 
desensitization was followed by a slower but sustained PKA-
mediated desensitization. Since rEP3hEP4-CtR did not acti-
vate any second messenger system, this second phase of sec-
ond messenger-activated kinase-dependent desensitization is 
missing in this system, explaining the transient nature of de-
sensitization. 
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